SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

Search

Smith & Nephew PLC

Abrir

1,328 -0.6

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1323

Máximo

1350.5

Indicadores-chave

By Trading Economics

Rendimento

296M

Vendas

3B

P/E

Médio do Setor

32.354

48.535

EPS

0.429

Rendimento de Dividendos

2.89

Margem de lucro

9.895

Funcionários

17,000

EBITDA

723M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+11.53% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.89%

3.96%

Próximos Ganhos

2 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

11B

Abertura anterior

1328.6

Fecho anterior

1328

Smith & Nephew PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de fev. de 2026, 22:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 de fev. de 2026, 22:36 UTC

Ganhos

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 de fev. de 2026, 22:32 UTC

Ganhos

Woodside Energy Fiscal Year Net Profit Falls 24%

23 de fev. de 2026, 23:58 UTC

Conversa de Mercado
Ganhos

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 de fev. de 2026, 23:58 UTC

Conversa de Mercado
Ganhos

Global Energy Roundup: Market Talk

23 de fev. de 2026, 23:47 UTC

Conversa de Mercado

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 de fev. de 2026, 23:43 UTC

Conversa de Mercado

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 de fev. de 2026, 23:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Crescent Capital Partners Owns 53% of ClearView Wealth

23 de fev. de 2026, 23:40 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 de fev. de 2026, 23:40 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 de fev. de 2026, 23:40 UTC

Conversa de Mercado

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 de fev. de 2026, 23:40 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 de fev. de 2026, 23:39 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 de fev. de 2026, 23:31 UTC

Ganhos

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 de fev. de 2026, 23:31 UTC

Ganhos

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 de fev. de 2026, 23:28 UTC

Ganhos

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 de fev. de 2026, 23:28 UTC

Ganhos

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 de fev. de 2026, 23:28 UTC

Ganhos

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 de fev. de 2026, 23:27 UTC

Ganhos

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 de fev. de 2026, 23:24 UTC

Conversa de Mercado

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 de fev. de 2026, 22:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 de fev. de 2026, 22:31 UTC

Ganhos

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 de fev. de 2026, 22:24 UTC

Ganhos

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy FY Underlying Ebitda A$700.9 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 de fev. de 2026, 22:21 UTC

Ganhos

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 de fev. de 2026, 22:21 UTC

Ganhos

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 de fev. de 2026, 22:20 UTC

Ganhos

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparação entre Pares

Variação de preço

Smith & Nephew PLC Previsão

Preço-alvo

By TipRanks

11.53% parte superior

Previsão para 12 meses

Média 1,490.57 GBX  11.53%

Máximo 1,650 GBX

Mínimo 1,290 GBX

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Smith & Nephew PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

7 ratings

5

Comprar

2

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat